12/05/2025 – AB Science reports its revenues for the year 2024 and provides an update on its activities Download PDF Post navigationPreviousPrevious post:AB Science will present new data from masitinib clinical program in ALS in two presentations at the 2025 ENCALS Annual MeetingNextNext post:CNews – Interview of Alain MoussyRelated PostsAB Science will hold a virtual conference on Thursday, October 16, 2025 from 2pm to 3pm CET to provide an update on the Phase 1 study with AB8939October 14, 2025Revenues for the first half of 2025 and update on AB Science’s activitiesOctober 10, 2025AB Science announces a slight delay in the publication of its 2025 half-year financial reportSeptember 30, 2025AB Science announces the successful completion of a 2.55 million euros private placementAugust 4, 2025AB Science receives regulatory approval from european countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AMLJuly 30, 2025AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALSJuly 24, 2025
AB Science will hold a virtual conference on Thursday, October 16, 2025 from 2pm to 3pm CET to provide an update on the Phase 1 study with AB8939October 14, 2025
AB Science announces a slight delay in the publication of its 2025 half-year financial reportSeptember 30, 2025
AB Science announces the successful completion of a 2.55 million euros private placementAugust 4, 2025
AB Science receives regulatory approval from european countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AMLJuly 30, 2025
AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALSJuly 24, 2025
